Skip to Main Content

Paper Details

Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
European Urology Focus
2
2023
ARAT, Androgen, Androgen Receptor, Androgen receptor, Metastatic Prostate Cancer, PATIENT, Patient, Patients, Prostate Cancer, androgen, androgen receptor, cancer, castration-resistant prostate cancer, mCRPC, mCSPC, metastatic castration-sensitive and castration-resistant prostate cancer, patient, patients
Author NameAffiliation
Neeraj AgarwalHuntsman Cancer Institute, University of Utah Health Care
  • 1 - 1

Datasets

Release 1.2